Standard BioTools Inc. (LAB) Stock

Standard BioTools Inc. specializes in the development, manufacturing, and global distribution of advanced instruments, consumables, reagents, and software tailored for researchers and clinical laboratories. The company's product portfolio includes cutting-edge analytical systems such as the Helios CyTOF system, Hyperion imaging systems, Hyperion tissue imagers, and flow conductors. They also offer a range of assays and reagents under brands like Maxpar, including Maxpar direct immune profiling assays and IMC panel kits designed for immuno-oncology research.

Complementing their analytical offerings, Standard BioTools provides preparatory instruments like the Juno systems, Biomark HD system, and EP1 system. Their integrated fluidic circuits (IFCs) include library preparation IFCs, genotyping IFCs, and various digital and dynamic array IFCs. The company also supports single-cell analysis with C1 systems and preparatory analytical instruments.

Founded in 1999 and headquartered in South San Francisco, California, Standard BioTools Inc., formerly known as Fluidigm Corporation, rebranded in April 2022 to better align with its evolving mission and product focus. With strategic license agreements with prestigious institutions such as the California Institute of Technology and Harvard University, Standard BioTools serves a diverse clientele including academic institutions, biopharmaceutical companies, and contract research organizations worldwide, contributing to advancements in research and clinical diagnostics.